Press Releases Investor Overview Press Releases Events and Presentations Upcoming Events Past Events Presentations Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Investor Overview Press Releases Events and Presentations Upcoming Events Past Events Presentations Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Year None20242023202220212020 June 24, 2024 Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) May 21, 2024 Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit May 2, 2024 Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update April 5, 2024 Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing April 5, 2024 Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition April 5, 2024 Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC March 13, 2024 Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update February 28, 2024 Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference January 31, 2024 Protara Therapeutics to Participate in Upcoming Investor Conferences November 30, 2023 Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology November 3, 2023 Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update October 23, 2023 Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Next page › Last page » Displaying 1 - 12 of 79 Print Print Email Alerts Email Alerts RSS Feeds RSS Feeds Email Page Email Page
Year None20242023202220212020 June 24, 2024 Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) May 21, 2024 Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit May 2, 2024 Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update April 5, 2024 Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing April 5, 2024 Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition April 5, 2024 Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC March 13, 2024 Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update February 28, 2024 Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference January 31, 2024 Protara Therapeutics to Participate in Upcoming Investor Conferences November 30, 2023 Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology November 3, 2023 Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update October 23, 2023 Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Next page › Last page » Displaying 1 - 12 of 79
June 24, 2024 Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 2, 2024 Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update
April 5, 2024 Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
April 5, 2024 Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
March 13, 2024 Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
November 30, 2023 Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology
November 3, 2023 Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
October 23, 2023 Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
